PGNX - Lantheus files U.S. application for PET imaging agent for prostate cancer

Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for prostate cancer.The application includes a request for Priority Review which, if granted, will shorten the review clock to six months from 10 months.Under the terms of the merger agreement, PGNX stockholders received one contingent value right ((CVR)) per share owned that pays out two cash amounts if net PyL sales exceed $100M in 2022 and $150M in 2023.

For further details see:

Lantheus files U.S. application for PET imaging agent for prostate cancer